Deep TMS (H1 Coil)
Major Depressive Disorder (MDD)
Key Facts
About BrainsWay
BrainsWay is a commercial-stage medical device company with a mission to boldly advance neuroscience to improve health and transform lives. Its core achievement is the development and FDA clearance of its Deep TMS platform for multiple psychiatric indications, establishing it as a leader in noninvasive neuromodulation. The company's strategy focuses on expanding its cleared indications, optimizing treatment protocols, and growing its global installed base through direct sales and strategic partnerships. BrainsWay leverages a robust body of clinical evidence to drive adoption among providers and payers.
View full company profileAbout BrainsWay
BrainsWay is a commercial-stage medical device company with a mission to boldly advance neuroscience to improve health and transform lives. Its core achievement is the development and FDA clearance of its Deep TMS platform for multiple psychiatric indications, establishing it as a leader in noninvasive neuromodulation. The company's strategy focuses on expanding its cleared indications, optimizing treatment protocols, and growing its global installed base through direct sales and strategic partnerships. BrainsWay leverages a robust body of clinical evidence to drive adoption among providers and payers.
View full company profileAbout BrainsWay
BrainsWay is a commercial-stage medical device company with a mission to boldly advance neuroscience to improve health and transform lives. Its core achievement is the development and FDA clearance of its Deep TMS platform for multiple psychiatric indications, establishing it as a leader in noninvasive neuromodulation. The company's strategy focuses on expanding its cleared indications, optimizing treatment protocols, and growing its global installed base through direct sales and strategic partnerships. BrainsWay leverages a robust body of clinical evidence to drive adoption among providers and payers.
View full company profileTherapeutic Areas
Other Major Depressive Disorder (MDD) Drugs
| Drug | Company | Phase |
|---|---|---|
| AL001 | Alzamend Neuro | Preclinical |
| EXXUA™ (gepirone ER) | Aytu BioPharma | Commercial |
| INV-202 (Oral & LAI) | Indivior | Preclinical |
| NeuroStar Advanced Therapy | Neuronetics | FDA Cleared |
| Gepirone ER | Fabre-Kramer Pharmaceuticals | NDA Submitted |
| Exablate Neuro | Insightec | Clinical Trial |
| BrightKaire Platform for Depression | NeuroKaire | Pre-clinical |
| Tyemvers (CKDB-501) | Healis Therapeutics | Pre-clinical |
| VENTURA-7 | New Hope Clinical Research | Phase 2/3 |
| DT-101 | Draig Therapeutics | Phase 2 |
| Major Depressive Disorder Program | Actipulse Neuroscience | Phase 3 |
| Flow tDCS Headset & App | Flow Neuroscience | Approved |